All News

AUA expressed 'strong opposition' to the health care reform legislation amendment eliminating the self-referral exemption for in-office ancillary services such as CT scans on the same day The Washington Post ran an article with the headline 'Doctors Reap Benefits By Doing Own Tests.'

The FDA has announced that boxed warnings are now included on labels of four botulinum toxin drug products, revising a previous safety alert on the products. The products also now include medication guides for patients, as mandated by FDA in April.

Endoscopic technology developer Karl Storz Endoscopy-America, Inc. has established a reseller agreement with Rivulet Communications, which produces high-definition medical video technology for hospital IP networks.

A second and final phase III, multicenter, double-blind, placebo-controlled study of PSD502 for premature ejaculation treatment has met all endpoints, according to Sciele Pharma and Plethora Solutions Holdings. Those endpoints include intra-vaginal ejaculation latency time and the index of premature ejaculation (IPE; ejaculatory control, sexual satisfaction, and distress domains).

Genentech, Inc. has earned FDA approval for bevacizumab (Avastin) plus interferon-alfa for treatment of metastatic renal cell carcinoma. Bevacizumab blocks the vascular endothelial growth factor (VEGF) protein responsible for tumor growth.

The better the relationship is between men and their health care provider, the greater their chance of receiving prostate cancer screening and the less likely they are to be diagnosed with advanced prostate cancer, regardless of their race, researchers from the University of North Carolina, Chapel Hill, and Roswell Park Cancer Institute, Buffalo, NY, reported in Cancer online.

In the 15 years following a radical prostatectomy, there is only a 12% mortality rate directly connected to prostate cancer, regardless of the cancer?s aggressiveness, according to a multicenter study appearing in the Journal of Clinical Oncology online. Comparatively, there was a 38% rate of non-cancer-related death in this same group of patients.